9MW3811
9MW3811 is an anti-IL-11 antibody with an EC50 of 0.1-0.3 nM against hIL-11, mouse, rat, and Canis IL-11. 9MW3811 blocks the JAK/STAT3 signaling pathway. 9MW3811 has a synergistic effect with anti-PD-1 antibodies, even in PD-1 non-responsive models. 9MW3811 shows antitumor effects in NSCLC, LUAD, lung cancer, and liver cancer models. 9MW3811 can be used for research on solid tumors and hepatocellular carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Species Reactivity
Human
IC50 & Target
[1]|
IL-11 |
STAT3 |
In Vitro
9MW3811 (30 min) blocked IL-11/IL-11Rα/gp130 complex formation in a blocking ELISA with an EC50 of 6.7 nM[1].
9MW3811 (6 h) dose-dependently inhibited STAT3-driven luciferase expression in IL-11Rα/STAT3-luc HEK293 cells[1].
9MW3811 blocks the formation of the IL-11/IL-11R/gp130 protein complex in ELISA[2].
9MW3811 inhibits IL-11-mediated signaling in a luciferase reporter cell assay[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HGC-27 cells
-
Concentration:Indicated concentrations (9MW3811)
-
Incubation Time:16 h (serum-free starvation); 20 min (37 °C, IL-11 + 9MW3811)
-
Result:Incubation with 9MW3811 dose-dependently reduced STAT3 phosphorylation.
Inhibition of IL-11-induced phosphorylated ERK was also observed.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 6-8 weeks old)[1]
-
Dosage:0.4 mg/kg; 2.0 mg/kg
-
Administration:i.p.; BIW×9
-
Result:Inhibited tumor growth at 2 mg/kg versus isotype control hIgG, with tumor growth inhibition (TGI) of 62%.
-
Animal Model:NOD/SCID (female, 6-8 weeks old)[1]
-
Dosage:10.0 mg/kg
-
Administration:i.p.; BIW×8
-
Result:Resulted in TGI of 50% in the LU5351 PDX model at 10 mg/kg.
Gene ID
Accession
Target
IL-11
Conjugated
Unconjugated
Application
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[9MW3811]
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
9MW3811 Related Classifications
HY-P992531 Related Classifications
Powered by Bioz